The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.
- Author:
Yong Tai KIM
1
;
Chul KIM
;
Joo Hyuk SOHN
;
So Young PARK
;
Soo Young PARK
;
Nae Choon YU
;
Young Sam KIM
;
Se Kyu KIM
;
Joon CHANG
;
Kil Dong KIM
;
Kyung Young CHUNG
;
Joo Hang KIM
Author Information
1. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. kjhang@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
ZD1839 (Iressa(R));
Non-small cell lung cancer
- MeSH:
Anemia;
Carcinoma, Non-Small-Cell Lung;
Disease Progression;
Disease-Free Survival;
Drug Therapy;
Exanthema;
Humans;
Nausea;
Neutropenia;
Small Cell Lung Carcinoma*;
Thrombocytopenia
- From:Cancer Research and Treatment
2003;35(6):502-506
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (Iressa(R)) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chemotherapy regimen. MATERIALS AND METHODS: Twenty-five patients who were refractory to previous chemotherapy were selected for this study. The eligible patients had an ECOG performance status of 0 to 2, and an appropriate end organ function. ZD 1839 (Iressa(R))250 mg/d was orally administered until the patients experienced disease progression or unacceptable toxicity. RESULTS: Twenty-five patients were analyzed. The median age of the patients was 57 years. The response rate was 12.0% with partial responses in 3 patients. Fourteen patients (56%) remained in the stable disease state and 8 patients progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological toxicities of grade 3 or 4 neutropenia, anemia and thrombocytopenia were absent. Non-hematological toxicities were grade 2 or 3 skin rashes in 10 (40.0%) patients and 1 (4.0%) patient and grade 3 nausea in 3 (12.0%) patients. No patient failed to continue chemotherapy due to any drug-related adverse events. CONCLUSION: The results suggest that ZD 1839 (Iressa(R)) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC patients refractory to previous chemotherapy regimens.
